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Abstract
Background: The rapid increase of industry-sponsored clinical research towards developing countries has led to
potentially complex ethical issues to assess. There is scarce evidence about the perception of these participants
about the ethical compliance, security, and protection. We sought to evaluate and contrast the awareness and
perception of participants and non-participants of industry-sponsored research trials (ISRT) on ethical, safety, and
protection topics.
Methods: A Cases-control survey conducted at twelve research sites in México. Previous and current participants of
ISRT (cases) as well as non-participants (controls) with one of four chronic diseases, were asked to complete the survey
which focused on ethical compliance and protection issues of ISRT, and the perception of participating in a trial.
Results: A total of 604 cases and 604 controls were surveyed. Cases significantly answered that ethics committees are
aware of what is happening in studies (50.5% vs. 33.8%, P =≤ 0.001), and that medical care of industry-sponsored
research trials is better than their usual medical care (77.2% vs. 38.2%, P = < 0.001). The same proportion of cases and
controls thought patients must receive economical reimbursement for participating in a research study (49.5% vs.
53.1%, P = 0.205). The informed consent of the pharmaceutical clinical trial was fully read by 90.4% of the cases.
Most cases were satisfied or very satisfied with their overall study participation (35.6 and 62.3%, respectively).
Conclusion: Previous and current participants of industry-sponsored research trials have a more positive attitude
towards ethics committees, the quality of medical care of the research trials, and the main purpose of economical
reimbursements, when compared to non-participants.
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Background
The major participation and transfer of pharmaceut-
ical industry clinical trials from developed to develop-
ing countries has occurred over the last three decades
[1–3]. In the last 10 years, clinical trial registry in
low- and low-middle income countries has increased
around 260% [4, 5]. Currently, one in four industry-
sponsored research trials (ISRT) include participants
outside of high-income countries [6, 7]. Furthermore,
clinical research protocols conducted in developing
countries frequently have a proportional major
participation in recruitment than developed countries
[2, 6]. There are many reasons to explain the progres-
sive growth of ISRT in developing countries: a signifi-
cantly lower cost for execution, the growth of the
pharmaceutical market in some of these regions, and
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the large populations interested in protocol participa-
tion as an alternative for their health care.
The rapid increase of ISRT in developing countries
has led to potential complex ethical issues and cases of
researcher misconduct [1]. Participants have an overall
good acceptance of ISRT, frequently identifying them as
a satisfactory way to receive high-quality medical care
[8]. Widespread poverty, lack of education and very
limited access to good-quality health services in many
developing countries make the ethical conduction
process of these protocols uncertain, particularly during
recruitment and informed consent (IC) phases [1].
Additionally, undue incentives and potential local
institutional review boards without a highly professional
performance are other factors. Even though some studies
have assessed the opinion of experts regarding these
topics, there is a paucity of evidence concerning the
participant’s perception [9–11].
We carried out a multicenter, disease-paired controlled
survey in México, in academic and non-academic
pharmaceutical clinical research sites. Our hypothesis
was that previous and current participants of research
trails would have different perspective and opinions
about clinical trials when compared to non-participants.
The primary endpoint was to contrast the awareness
and perception of participants and non-participants of
the ISRT on a wide variety of ethical, safety and protec-
tion topics in a large population with one out of four
highly prevalent chronic diseases: type 2 diabetes
(T2DM), arterial hypertension (HT), chronic obstructive
pulmonary disease (COPD), and rheumatoid arthritis
(RA). Secondary endpoints were to contrast their per-
ception by gender, age, disease, and research site.
Methods
Design and validation of the survey
We report the second section of a multicenter survey on
clinical trial perceptions, which focused on ethical com-
pliance and protection issues of ISRT, along with the
overall perception of participating in a trial. Rationale, de-
sign, and detailed validation of the survey have been previ-
ously published [8]. Validation of the survey process
consisted of a two-phase pre-pilot study and a pilot study.
The original draft was tested in two groups of 7–8 partici-
pants each (80% of which were previously involved in a
clinical trial). Twelve individual semi-structured inter-
views were conducted at 6 out of 12 research sites (2 in-
terviews per site). In order to cover the four main diseases
(T2DM, HAS, COPD, RA) that our survey focused on in
our pilot study, these 6 centers were randomly selected
based on their specialty and the clinical trials that they
were conducting. Questions were revised and modified
considering key points mentioned by participants in each
stage. Thereafter, the modified questionnaire was applied
to 30 individuals who fulfilled the same eligibility criteria.
Due to the amount of information, the diversity of issues,
and for better communication to readers, the results of
the survey were divided into two documents.
Study participants and research sites
Institutional review board (IRB) approval was obtained.
Comité de Ética en Investigación del Hospital Universi-
tario “Dr Jose Eleuterio González”, CONBIOETICA
-19-CEI-001-20,160,404. All participants’ sites were ap-
proved by our IRB before participating in the recruit-
ment of the study. All participants provided written
informed consent. Men and women, aged 18 to 80 years,
who have lived in Mexico the last 10 years and were di-
agnosed with T2DM, HT, COPD, or RA, were eligible
for participation. Cases were former or current partici-
pants of phase II or III pharmaceutical clinical trials who
had attended at least their sixth visit. If participants had
more than one of the diseases included in this study,
they were assigned to the disease subgroup that matched
with the clinical trial. Disease-matching controls had
never participated or been invited to participate in
pharmaceutical clinical trials. They were recruited while
attending the primary care or specialty outpatient clinics
of the clinical research sites. All participants answered
the self-survey independently. The surveys were applied
at 12 research sites in México. Each facility had a profes-
sional pharmaceutical research team and had been
conducting pharmaceutical research studies for at least
10 years. All research sites also offered primary care and
specialty outpatient clinic services. It is noteworthy that
more than 75% of the population have access to health
care, while the rest of them have access public health
system of national coverage.
Study protocol and procedures
Cases were recruited while attending their research
study site and controls at the outpatient clinics. Both
cases and controls were recruited in a consecutive man-
ner while attending their research study site and at the
outpatient clinics, respectively. One hundred surveys
were applied in each research site: 50 for cases and 50
for controls. A staff member, not involved in the partici-
pants’ clinical research, obtained the participant’s demo-
graphic data, applied the survey, clarified any question
and ensured survey completion. All surveys were sent to
a central site for data management and analysis. Cases
and controls answered 9 multiple-choice questions, each
with 2 to 9 response options. The cases group answered
12 additional questions focused on their satisfaction and
experience while participating in a research clinical trial.
Neither cases nor did controls receive economical reim-
bursement for their participation in our survey study.
Our study was conducted separately and independently
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of any pharmaceutical clinical trials that cases were
taking part at the moment of the survey application.
Statistical analysis
Statistical analyses were done using IBM SPSS Statistics
20.0 (IBM Corporation, Armonk, NY). Continuous
variables are expressed as means ± standard deviation;
categorical variables are expressed as frequencies and
percentages. Categorical variables were compared using
the Chi-square test and the Fisher exact test for 2 × 2
tables. For quantitative comparative variables, Student’s t
test or the Mann Whitney U test were employed;
distribution of numerical variables was confirmed by the
Kolmogorov-Smirnov test. A P value ≤0.05 was consid-
ered statistically significant.
Results
Study population
The demographic and clinical characteristics of the
study population are shown in Table 1. Every patient
approached agreed to answer the survey. A total of 604
cases and 604 controls participated. Except for mean age
(cases were older than controls, 54.9 ± 13.9 vs. 47.1 ±
15.5 years, respectively, P ≤ 0.001), there was no other
statistically significant difference in the demographic
variables. Female to male ratio in both groups was 2:1.
Cases who were participating in a pharmaceutical
clinical trial for the first time accounted for 65.4% of the
whole group. Survey answers obtained in the whole
study group are shown in Table 2. Survey answers
specific for the cases group are shown in Table 3. This
shows the two most and least common answers for
each question. Unless otherwise stated statistical ana-
lysis by sex, age, and disease category was not statisti-
cally different.
Survey questions for cases and controls
Cases significantly answered that ethics committees (EC)
are aware of what is happening in the studies (50.5% vs.
33.8%, P = < 0.001), that research physicians are qualified
and evaluated by international pharmaceutical compan-
ies (90.0% vs. 62.1%, P = 0.001), that medical care of the
ISRT is much better than their usual medical care
(77.2% vs. 38.2%, P ≤ 0.001), that participating in a clin-
ical trial is an adequate way to receive medical care for
their disease (99.2% vs. 88.9%, P = 0.001); the reason was
that participants get closer medical care (51.6% vs.
32.7%, P = < 0.001), but the main inconvenience was that
treatments are interrupted once the research is con-
cluded (50% vs. 19.4%, P = 0.005). They also answered
that economical reimbursement was an acceptable sup-
portive stimulus only when it is justified (45.5% vs.
Table 1 Demographic and clinical characteristics of the study population
Characteristic Study population T2DM COPD RA HT
Cases Controls Cases Controls Cases Controls Cases Controls Cases Controls
n = 604 n = 604 n = 151 n = 151 n = 151 n = 151 n = 151 n = 151 n = 151 n = 151
Age, mean ± SD (years) 54.9 ± 13.9 47.1 ± 15.5a 52.2 ± 12.8 46.6 ± 15.7a 60.3 ± 14.2 53.1 ± 16.7a 50.1 ± 13.4 41.6 ± 15.3a 56.8 ± 13.1 47 ± 12.1a
Age group, n (%)
< 50 years 216 (35.8) 320 (53.0)a 68 (45.0) 83 (55.0) 31 (20.5) 57 (37.7)a 71 (47.0) 103 (68.2)a 46 (30.5) 77 (51.0)a
> 50 years 388 (64.2) 284 (47.0) 83 (55.0) 68 (45.0) 120 (79.5) 94 (62.3) 80 (53.0) 48 (31.8) 105 (69.5) 74 (49.0)
Sex, n (%)
Female 377 (62.4) 394 (65.2) 101 (66.9) 95 (62.9) 69 (45.7) 92 (60.9)b 126 (83.4) 110 (72.8)b 81 (53.6) 97 (64.2)
Male 227 (37.6) 210 (34.8) 50 (33.1) 56 (37.1) 82 (54.3) 59 (39.1) 25 (16.6) 41 (27.2) 70 (46.4) 54 (35.8)
Years of education, n (%)
< 9 years 363 (60.1) 341 (56.5) 90 (59.6) 82 (54.3) 89 (58.9) 76 (50.3) 90 (59.6) 85 (56.3) 94 (62.3) 98 (64.9)
> 9 years 241 (39.9) 263 (43.5) 61 (40.4) 69 (45.7) 62 (41.1) 75 (49.7) 61 (40.4) 66 (43.7) 57 (37.7) 53 (35.1)
Health care, n (%)
Yes 476 (78.8) 453 (75) 122 (80.8) 118 (78.1) 116 (76.8) 121 (80.1) 112 (74.2) 116 (76.8) 126 (83.4) 98 (64.9)a
No 128 (21.2) 151 (25) 29 (19.2) 33 (21.9) 35 (23.2) 30 (19.9) 39 (25.8) 35 (23.2) 25 (16.6) 53 (35.1)
Previous clinical trial participation (case group only), n (%)
One 395 (65.4) 89 (58.9) 89 (58.9) 119 (78.8) 98 (64.9)
Two to three 196 (32.5) 60 (39.7) 56 (37.1) 28 (18.5) 52 (34.4)
Three to six 10 (1.7) 2 (1.3) 5 (3.3) 2 (1.3) 1 (0.7)
More than six 3 (0.5) 0 (0) 1 (0.7) 2 (1.3) 0 (0)
aP ≤ 0.001; bP ≤ 0.05
T2DM Type 2 diabetes mellitus, COPD chronic obstructive pulmonary disease, RA rheumatoid arthritis, HT hypertension
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Table 2 Comparison of the answers between cases and controlsa
Questions and answers Cases Controls P value
n = 604 n = 604
Ethics Committee
1. What is your opinion about the Ethics Committees?
I think most of the time they are aware of what is happening in these studies 305 (50.5) 204 (33.8) < 0.001
I am aware they exist but I do not know their function 133 (22) 165 (27.3)
I do not know what an Ethics Committee is 111 (18.4) 127 (21)
I am aware that they exist but I am not sure if they fulfill their functions 45 (7.5) 56 (9.3)
I think most of the time they are not aware of what is happening in these studies 4 (0.7) 27 (4.5)
I am sure that most of the time they are not responsible of fulfilling their function 5 (0.8) 24 (4)
Other opinion 1 (0.2) 1 (0.2)
2. Which is the main function of an Ethics Committee?
To ensure that research physicians and their collaborators are adequately qualified 180 (29.8) 192 (31.8) 0.293
I do not know precisely what responsibilities they must fulfill 175 (29) 189 (31.3)
To review whether the research study characteristics provide benefits to the participants 87 (14.4) 63 (10.4)
To approve or deny permission to execute a research study 67 (11.1) 62 (10.3)
To register the experimental drug’s adverse reactions as they occur 59 (9.8) 54 (8.9)
To interrupt the research study in case they consider that participants could be at risk 30 (5) 39 (6.5)
To make sure that the informed consent documents are easy to understand 4 (0.7) 5 (0.8)
Other function 2 (0.3) 0 (0)
Research studies’ medical care
3. What is your opinion about the research physicians that participate in pharmaceutical industry-sponsored studies?
They must be qualified physicians evaluated by international pharmaceutical companies 545 (91.3) 374 (62.1) < 0.001
I have no opinion on the matter because I do not know any research physician 25 (4.2) 109 (18.1)
They are like any other physician, the only difference is that they do this activity 20 (3.4) 67 (11.1)
I believe that most of them participate in this kind of studies only because of the money they are paid 5 (0.8) 41 (6.8)
I think that they must not be very good physicians 2 (0.3) 10 (1.7)
Other opinion 0 (0) 1 (0.2)
4. What is your opinion about the medical care that pharmaceutical industry research studies’ participants receive?
It is much better than private medical care 464 (77.2) 230 (38.2) < 0.001
It must be the same as private medical care 81 (13.5) 157 (26.1)
I do not know if it is better or worse than private medical care 14 (2.3) 128 (21.3)
I believe the most important fact is that the medical care is free of charge 33 (5.5) 48 (8)
It is inferior to private medical care 9 (1.5) 36 (6)
Other reason 0 (0) 3 (0.5)
5. Do you consider that participating in a clinical trial is an adequate way for patients to get medical care
Yes 599 (99.2) 537 (88.9) < 0.001
No 5 (0.8) 67 (11.1)
6. Why do you believe that participating in a clinical trial is an adequate way to get medical care?
Because participants receive closer follow-up than with any other medical center 308 (51.6) 175 (32.7) < 0.001
Because participants receive new treatments that offer more advantages than any other medication available 71 (11.9) 107 (20)
Because international scientists are monitoring the medication’s effects 93 (15.6) 79 (14.8)
Because these are very strict studies where all medical adverse reactions are monitored 31 (5.2) 47 (8.8)
Because the physician is available and can be found easily 53 (8.9) 23 (4.3)
Although it is not ideal, it is the best way to get medical care if you lack economical resources to pay for it 12 (2) 51 (9.5)
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36.9%, P ≤ 0.001) or necessary to cover extra transporta-
tion costs (39.7% vs. 30.3%, P ≤ 0.001).
Controls when contrasted to cases, significantly an-
swered that a major proportion of physicians partici-
pate in these studies because of the money they are
paid (6.8% vs. 0.8%, P ≤ 0.001), that medical care of
the ISRT is inferior to typical medical care (6.0% vs.
1.5%, P ≤ 0.001). They also thought that participating
was an adequate way to get medical care because they re-
ceive new treatment options (20.0% vs. 11.9%, P ≤ 0.001),
that it was unreasonable because of the risks of experi-
mental drugs compared to non-investigational treatments
(44.8% vs. 0%, P = 0.005), and that they must receive an
economical reimbursement as a compensation for
risking their health (12.1% vs. 4%, P ≤ 0.001), and a
fair payment for participating in a research study
(6.5% vs. 2.2%, P ≤ 0.001).
There was no difference between cases and controls
regarding the main function of the EC (to ensure the
qualification of research physician and collaborators,
29.8% vs. 31.8%, P = 0.293), and that they must receive
economical reimbursement for participating in a
research study (49.5% vs. 53.1%, P = 0.205). However, a
higher proportion of controls thought that EC were not
aware of what happens in clinical trials (cases 0.7% vs.
controls 4.5%, P ≤ 0.001) or that they were not respon-
sibly fulfilling their function (cases 0.8% vs. controls 4%,
P ≤ 0.001).
Survey questions only for cases
Cases were invited to pharmaceutical research studies
mainly by a clinical researcher involved in the study
(51.4%), and by other study participants (19%). They
decided to participate because it is the best way to get
medical care (36.8%), followed by “physician care of the
patient is more cautious” (26.3%). The least given answer
was because everything is free (3.1%). The IC of the
pharmaceutical clinical trial was fully and deeply read by
90.4% of the cases. Those participants who did not fully
read the IC (9.6%) expressed that they skipped reading
some parts of the IC letter because they trusted their
physicians (56.9%), followed by not having enough time
to read it (19%). The researcher explained the protocol,
risks, and benefits as well as their rights and obligations
as a participant most of the times in more than 30 min
(43.4%). Nevertheless, in some cases this time was
Table 2 Comparison of the answers between cases and controlsa (Continued)
Questions and answers Cases Controls P value
n = 604 n = 604
Because they perform a lot of laboratory tests free of charge 19 (3.2) 34 (6.4)
Because physicians that do medical research are more qualified 10 (1.7) 19 (3.6)
7. Why do you believe that participating in a clinical trial is not an adequate way to get medical care?
Because of potential risks that are not present when using authorized treatments 0 (0) 30 (44.8) 0.005
Because a lot of unnecessary laboratory tests are performed 1 (16.7) 16 (23.9)
Because treatments are interrupted once the research study is over 3 (50) 13 (19.4)
Because they require you to assist to a lot of unnecessary consults 1 (16.7) 7 (10.4)
Did not answered 1 (16.7) 0 (0)
Other reason 0 (0) 1 (1.5)
Economical Reimbursement
8. Do you believe that you must receive an economical reimbursement (money) for participating in a research study?
Yes 299 (49.5) 321 (53.1) 0.205
No 305 (50.5) 283 (46.9)
9. What is your opinion about receiving an economical reimbursement (money) for participating in a research study?
There should not be monetary supportive stimuli unless they are strictly justified 274 (45.4) 223 (36.9) < 0.001
That it is necessary in order to cover the costs of extra transportation that participating in a study implies 240 (39.7) 183 (30.3)
I think it is payment for risking my health 24 (4) 73 (12.1)
Other reason 17 (2.8) 36 (6)
I think it is a good payment for participating in a research study 13 (2.2) 39 (6.5)
I think it is used to convince some people to enroll in a research study 13 (2.2) 36 (6)
Monetary supportive stimuli are not proportionate to the potential risks that participating in a research study
implies
23 (3.8) 14 (2.3)
aData are given as n (%)
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Table 3 Comparison of survey questions only for cases by disease groupa
Questions and answers Disease Group
Total T2DM COPD RA HT P value
(n = 604) (n = 151) (n = 151) (n = 151) (n = 151)
Enrollment
10. How were you invited to participate in your current or most recent research study?
By a clinical researcher participating in the study. 190 (31.5) 43 (28.5) 51 (33.8) 76 (50.3) 20 (13.2) < 0.001
In the research physician’s private consult. 120 (19.9) 25 (16.6) 36 (23.8) 26 (17.2) 33 (21.9)
A patient who participates in the research study invited me. 115 (19) 52 (34.4) 18 (11.9) 14 (9.3) 31 (20.5)
Other media. 65 (10.8) 14 (9.3) 14 (9.3) 9 (6) 28 (18.5)
In a disease detection campaign. 45 (7.5) 9 (6) 12 (7.9) 6 (4) 18 (11.9)
In a private medical consult. 39 (6.5) 5 (3.3) 9 (6) 6 (4) 19 (12.6)
Notice published at a hospital. 16 (2.6) 2 (1.3) 5 (3.3) 7 (4.6) 2 (1.3)
Newspaper advertisement. 13 (2.2) 1 (0.7) 5 (3.3) 7 (4.6) 0 (0)
Radio advertisement. 1 (0.2) 0 (0) 1 (0.7) 0 (0) 0 (0)
Notice published online. 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Television advertisement. 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
11. Why did you decided to participate in your current research study?
Because this is the best way to get medical care. 222 (36.8) 54 (35.8) 54 (35.8) 56 (37.1) 58 (38.4) < 0.001
Because the physician’s care is more cautious. 159 (26.3) 52 (34.4) 41 (27.2) 31 (20.5) 35 (23.2)
Because I have not responded to available treatments. 112 (18.5) 21 (13.9) 15 (9.9) 28 (18.5) 48 (31.8)
Because my participation aids scientific medical progress. 65 (10.8) 11 (7.3) 25 (16.6) 22 (14.6) 7 (4.6)
Because I have no other way to get clinical care. 23 (3.8) 5 (3.3) 8 (5.3) 10 (6.6) 0 (0)
Because everything is free. 19 (3.1) 7 (4.6) 7 (4.6) 2 (1.3) 3 (2)
Other reason. 4 (0.7) 1 (0.7) 1 (0.7) 2 (1.3) 0 (0)
Informed Consent
12. Have you fully read the informed consent letter required to accept enrolling in the research study?
Yes 546 (90.4) 138 (91.4) 137 (90.7) 129 (85.4) 142 (94) 0.079
No 58 (9.6) 13 (8.6) 14 (9.3) 22 (14.6) 9 (6)
13. Why did you not read the informed consent letter?
Because I fully trust that my physician would not put my health at risk. 33 (56.9) 4 (30.8) 9 (64.3) 14 (63.6) 6 (66.7) 0.115
Because I did not have enough time to read it. 11 (19) 6 (46.2) 2 (14.3) 2 (9.1) 1 (11.1)
Because the document was very long. 8 (13.8) 2 (15.4) 3 (21.4) 1 (4.5) 2 (22.2)
Other reason. 3 (5.2) 1 (7.7) 0 (0) 2 (9.1) 0 (0)
Because I did not understand it, the text was not clear. 3 (5.2) 0 (0) 0 (0) 3 (13.6) 0 (0)
14. How much time did the research physician take to explain the research study’s process, risks and benefits, as well as your rights and
obligations as a participant?
More than 30min. 262 (43.4) 56 (37.1) 33 (21.9) 64 (42.4) 109 (72.2) < 0.001
20 to 30 min. 130 (21.5) 50 (33.1) 33 (21.9) 25 (16.6) 22 (14.6)
10 to 20 min. 107 (17.7) 27 (17.9) 33 (21.9) 35 (23.2) 12 (7.9)
No more than 10min. 97 (16.1) 17 (11.3) 46 (30.5) 26 (17.2) 8 (5.3)
Less than 5 min. 8 (1.3) 1 (0.7) 6 (4) 1 (0.7) 0 (0)
15. How satisfied are you with the explanation received about the research study’s process, risks and benefits, as well as the protection you have in
case of an adverse reaction related to the experimental drug?
Very satisfied. 326 (54) 81 (53.6) 78 (51.7) 70 (46.4) 97 (64.2) 0.043
Satisfied. 249 (41.2) 67 (44.4) 63 (41.7) 68 (45) 51 (33.8)
Neither satisfied nor unsatisfied. 20 (3.3) 3 (2) 6 (4) 10 (6.6) 1 (0.7)
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Table 3 Comparison of survey questions only for cases by disease groupa (Continued)
Questions and answers Disease Group
Total T2DM COPD RA HT P value
(n = 604) (n = 151) (n = 151) (n = 151) (n = 151)
Unsatisfied. 7 (1.2) 0 (0) 3 (2) 2 (1.3) 2 (1.3)
Very unsatisfied. 2 (0.3) 0 (0) 1 (0.7) 1 (0.7) 0 (0)
Cases’ experience participating in an industry-sponsored research trial
16. How satisfied are you with your participation in this research study?
Very satisfied. 376 (62.3) 90 (59.6) 89 (58.9) 83 (55) 114 (75.5) 0.009
Satisfied. 215 (35.6) 61 (40.4) 58 (38.4) 61 (40.4) 35 (23.2)
Neither satisfied nor unsatisfied. 6 (1) 0 (0) 1 (0.7) 4 (2.6) 1 (0.7)
Unsatisfied. 3 (0.5) 0 (0) 1 (0.7) 2 (1.3) 0 (0)
Very unsatisfied. 4 (0.7) 0 (0) 2 (1.3) 1 (0.7) 1 (0.7)
17. How satisfied are you with the time your research physician dedicates you?
Very satisfied. 413 (68.4) 106 (70.2) 94 (62.3) 90 (59.6) 123 (81.5) 0.003
Satisfied. 179 (29.6) 44 (29.1) 53 (35.1) 57 (37.7) 25 (16.6)
Neither satisfied nor unsatisfied. 5 (0.8) 1 (0.7) 1 (0.7) 2 (1.3) 1 (0.7)
Unsatisfied. 3 (0.5) 0 (0) 0 (0) 1 (0.7) 2 (1.3)
Very unsatisfied. 4 (0.7) 0 (0) 3 (2) 1 (0.7) 0 (0)
18. How satisfied are you with your research physician’s sense of humanity?
Very satisfied. 466 (77.2) 124 (82.1) 113 (74.8) 103 (68.2) 126 (83.4) 0.019
Satisfied. 133 (22) 27 (17.9) 36 (23.8) 47 (31.1) 23 (15.2)
Neither satisfied nor unsatisfied. 1 (0.2) 0 (0) 1 (0.7) 0 (0) 0 (0)
Unsatisfied. 2 (0.3) 0 (0) 0 (0) 0 (0) 2 (1.3)
Very unsatisfied. 2 (0.3) 0 (0) 1 (0.7) 1 (0.7) 0 (0)
19. How easy is to talk to your research physician? (Availability)
Very easy. 447 (74) 114 (75.5) 108 (71.5) 97 (64.2) 128 (84.8) 0.021
Easy. 143 (23.7) 36 (23.8) 37 (24.5) 49 (32.5) 21 (13.9)
Neither easy nor difficult. 10 (1.7) 1 (0.7) 5 (3.3) 3 (2) 1 (0.7)
Difficult. 2 (0.3) 0 (0) 0 (0) 1 (0.7) 1 (0.7)
Very difficult. 2 (0.3) 0 (0) 1 (0.7) 1 (0.7) 0 (0)
20. How satisfied are you when talking to the research physician?
Very satisfied. 457 (75.7) 117 (77.5) 105 (69.5) 106 (70.2) 129 (85.4) 0.019
Satisfied. 136 (22.5) 34 (22.5) 40 (26.5) 41 (27.2) 21 (13.9)
Neither satisfied nor unsatisfied. 5 (0.8) 0 (0) 2 (1.3) 3 (2) 0 (0)
Very unsatisfied. 4 (0.7) 0 (0) 3 (2) 1 (0.7) 0 (0)
Unsatisfied. 2 (0.3) 0 (0) 1 (0.7) 0 (0) 1 (0.7)
21. How satisfied are you with the results obtained regarding the research medical care of your disease?
Very satisfied. 444 (73.5) 110 (72.8) 104 (68.9) 103 (68.2) 127 (84.1) 0.055
Satisfied. 144 (23.8) 36 (23.8) 41 (27.2) 43 (28.5) 24 (15.9)
Neither satisfied nor unsatisfied. 12 (2) 5 (3.3) 4 (2.6) 3 (2) 0 (0)
Very unsatisfied. 3 (0.5) 0 (0) 2 (1.3) 1 (0.7) 0 (0)
Unsatisfied. 1 (0.2) 0 (0) 0 (0) 1 (0.7) 0 (0)
aData are given as n (%)
T2DM Type 2 diabetes mellitus, COPD chronic obstructive pulmonary disease, RA rheumatoid arthritis, HT hypertension
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reduced to 10 min (16.1%) or less (1.3%). Regarding
satisfaction, most cases were satisfied or very satisfied
with their overall study participation (35.6 and 62.3%, re-
spectively), the time research physicians took to explain
the research study (41.2 and 54%, respectively), the re-
searcher or staff availability (23.7 and 74%, respectively)
the sense of humanity of the research physician (22 and
77.2%, respectively), and the outcomes obtained through
the medical care received (23.8 and 73.5% respectively).
Discussion
In this multicenter, cross-sectional, comparative survey
study conducted in a developing country, participants of
ISRT were more aware than controls of the responsibil-
ity and function of the EC in pharmaceutical industry
trials, the higher quality of their medical services and
the researcher’s physicians, the protection by the EC,
safety and overall satisfaction during protocol participa-
tion, and the reasons behind economical reimbursement.
More than half of the ISRT conducted in low- and
low-middle income countries focus on investigational
drugs for chronic diseases [6]. Although several studies
have assessed ISRT in developing countries, they focus
on assessing patients who are frequently non-responders
to standard-of-care medications, and consequently,
forced to explore investigational drugs (e.g., cancer, type
C hepatitis) [12, 13]. A strength of our study is that our
surveyed participants had T2DM, HT, COPD and RA,
very common disorders with many accessible thera-
peutic choices and who decided to be recruited into
clinical trials despite all these good available medications
for their diseases. Therefore, their responses might
better reflect the perception of their participation in
pharmaceutical ISRT. A recent study by Wu E. et al. of
1200 participants with hepatitis C from the United
States and urban and rural China, assessed the perspec-
tives and concerns of research participants and
non-participants about ISRT [12]. They found that while
US participants were concerned about safety, privacy,
and confidentiality, Chinese had concerns about
self-benefit, free medical care, and economical reim-
bursement [12]. These findings show that sociocultural
and economic factors have a huge influence on how
people see clinical research. A previous report of the
first section of the present survey showed that
participation in this type of studies improves their fu-
ture perception [8]. Other authors have observed this
finding [5, 12, 14, 15]. Moreover, Kost et al. in 2014
assessed the experiences of participants in NIH-sup-
ported clinical research centers. They distributed al-
most 19,000 surveys obtained response from 29% finding
that 73% top-rated their overall research experience and
up to 63% would recommend participating in a clinical
trial [14]. Likewise, the 2017 CISCRP’s Perceptions &
Insights Study assessed more than 12,000 patients, mostly
previous participants of clinical trials (82%) with diverse
medical conditions via an online international survey.
They reported that 54% would definitely recommend par-
ticipating in clinical research and that 33% are somewhat
willing and 59% are very willing to participate in another
study [15]. These studies disclose the shared similarities
and notable differences among research participants’
perspectives worldwide.
Ethical oversight has been a concern since the begin-
ning of the globalization in pharmaceutical clinical re-
search and, although ethical compliance has improved
over the last decade, areas of opportunities remain to be
revised [1, 9, 11, 16]. The majority of our study popula-
tion had an overall positive perception about EC. Never-
theless, almost one in five cases and controls did not
know what an EC was, as well as their functions and re-
sponsibilities. Current and potential participants seems
to lack awareness of the safety monitoring that is
entailed in clinical trials [17]. Similarly, when Wu et al.
asked their study population to rank how relevant it was
for them to be informed that a study received EC review
before the research starter visit, 95% of US patients con-
sidered it important or very important, compared to less
than 80% in rural and urban Chinese [12]. This finding
highlights the sense of safety and validity that EC repre-
sent to patients who are aware of their key role for trial
conduction.
Mandava et al. reported that the educational level of
participants or living in a developed or developing coun-
try does not seem to affect their research trial compre-
hension [18]. Moreover, a key factor associated to better
protocol understanding of IC letter is the amount of
time designated to explain the study protocol [19]. In
our study, most of the time, more than 20–30min were
designated for explanation to each participant; this could
possibly explain their high level of satisfaction with the
information received, the amount of time researchers
dedicated to them as well as the sense of humanity and
availability of the researchers. Similar to the outpatient
clinic scenario, translating the shared decision-making
approach to research trials promotes trust and em-
powers the choice of the patient for accepting or declin-
ing to participate [20].
In this study, most controls and virtually all cases con-
sidered that participating in a clinical trial is an adequate
way for patients to get medical care for their condition,
mainly because of the closer follow-up they receive. Cox
and McDonald conducted in-depth interviews of previ-
ous research participants in order to obtain their narra-
tives of being participants of clinical trials and clustered
the results into four categories: “surviving”, “being con-
scripted”, “being a good citizen” and “health consuming”
[21]. The narrative of our study population could be
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categorized as “health consuming”: patients with a
chronic illness that has treatment options that could be
managed in a more effective way through research, even
perceiving trials as part of their standard care [21] This
scenario could be more prevalent in years to come. To
date, it is undeniable the considerable amount of
patients worldwide who lack access to qualified health
services [22]. Participants from this and others studies
have stated that research trials enables them to get
access to otherwise unreachable medical services [12].
Therefore, even if it is not their goal, ISRT improve the
health conditions of some untreated patients through
their higher-quality medical care.
Both cases and controls were split when asked whether
or not economical reimbursement was a must for them
to participate in a research study. Patients often view
economical reimbursement as a sign of appreciation for
the time spent attending the appointments of their re-
search trial, which did not “blind” them on the risks that
implies participating in an ISRT [23, 24]. On the other
hand, members of Institutional Review Boards disap-
prove economical reimbursements because of their po-
tential use as an undue incentive to enroll patients.
Interestingly, most of our study population expressed a
more balanced opinion, stating that all monetary sup-
portive stimuli have to be strictly justified. As suggested
by Wertheimer, economic reimbursements should be in-
dividualized and established for each study based on a
risk-benefit evaluation, in order to show respect for the
autonomy of the participants [25]. Therefore, it could be
argued that it is ethically correct and beneficial to pursue
the implementation of fair economical reimbursements
while designing clinical trials, even in the setting of
developing countries.
Regarding participants’ satisfaction, most cases in our
study expressed that they were satisfied or very satisfied
with their overall participation (97.9%) and with the re-
sults obtained (97.3%). These results strongly contrasts
with the opinions of research participants in developed
countries. Kost et al., reported 75% of participants
top-rated their overall experience [14]; in the 2015
CISCRP survey, less than half of the participants consid-
ered that their clinical research study greatly exceeded
(19%) or exceeded their expectations (27%) [5]. Although
more studies are needed, it seems that research partici-
pants of ISRT conducted in low- and low-middle income
countries more positively perceive and are more satisfied
with their role as participants and the overall experience
of participating in a clinical trial than their peers from
developed countries.
This study has several limitations. First, the trail design
does not permit to study the influence that participating
in a clinical trials have directly on patients’ perceptions
and opinions about clinical trials and only associations
can be made. Future studies that assess patients’ percep-
tion before and after their first participation in a clinical
trial could clarify this issue. Second, although the study
was validated in a pilot study, there are still chance of
misunderstanding, or skipping overall the whole survey.
Nevertheless, the majority of surveys were answered
with a staff member around in order to clarify questions
and ensure the survey were correctly and fully answered.
Third, study sample was not calculated, instead we draw
a convenience sample. Nevertheless, we considered our
population to be large enough in order to reduce the
possibility of a sampling error to occur. Fourth, al-
though, the majority of the cases in our study were
current participating in their first clinical trials and were
blind to treatment, cases that were at their second or
further clinical trial were not assessed for previous ex-
posure to placebo or active substance. The influence that
had been under placebo vs active substance may have on
participants’ perceptions and opinions about research
trials is a strong point to be assessed which future
studies must approach. Fifth, because cases must have
attended at least their sixth visit in order to be included
in the study, some questions about process that occur
early in the study (e.g. informed consent, enrollment,
etc.) could carry a memory bias. Nevertheless, we con-
sidered that being at their six visit was an appropriate
time to have gained experience in what participating in a
clinical trial really means, justifying not asking cases
right away after their enrollment in clinical trials.
Conclusion
Previous and current participants of ISRT have a more
positive attitude towards ethics committees, the quality of
medical care of the research trials, and the main purpose
of economical reimbursements than non-participants. The
gratifying experiences of participants in previous or
current clinical trials may be accountable for this. In both
groups, however, there is still a wide spectrum of oppor-
tunities to improve the perception about their participa-
tion. Special programs addressed to the population in our
country and likely in low-middle income countries regard-
ing the right way to conduct recruitment, the IC proced-
ure, benefits, autonomy, freedom to participate and to
drop out from the study, and other related topics are
clearly needed, assessing scientifically the value of each of
these programs. Moreover, it is necessary to assess percep-
tion of participants in non-professionalized vs. profession-
alized research sites in a multinational trial.
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